• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Fusion Pharmaceuticals Acquires IPN-1087

    Strata Oncology Unveils Strata PATH Trial

    Alimentiv Acquires McDougall Scientific

    Q BioMed Inks Strontium89 Supply Pact

    PCI Pharma Services Appoints SVP, CFO
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    WuXi AppTec Completes OXGENE Acquisition

    Celonic Group Announces Plans for New Facility in Switzerland

    BMS Expands Cell Therapy Manufacturing Capabilities

    Novo Nordisk Invests $80M in Tablet Production

    Arcline Investment Acquires ChargePoint Technology
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reshaping the Pharmaceutical Supply Chain

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Strata Oncology Unveils Strata PATH Trial

    Alimentiv Acquires McDougall Scientific

    WuXi AppTec Completes OXGENE Acquisition

    Live Webinar - Formulation Strategies for Poorly Soluble Molecules

    Celonic Group Announces Plans for New Facility in Switzerland
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Cytovance Biologics

    Emergent BioSolutions

    Reed-Lane

    Baxter BioPharma Solutions

    Aphena Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Federal Equipment Company

    Baxter BioPharma Solutions

    Emergent BioSolutions

    Alcami

    Adare Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    CMOs Hiring Constraints: Cell Therapy Manufacturing Expecting Future Challenges

    Technically trained staff needed to run complex manufacturing platforms, automation

    CMOs Hiring Constraints:  Cell Therapy Manufacturing Expecting Future Challenges
    Figure 1. (Source: 13th Annual Report and Survey of Biopharmaceutical Manufacturing, April 2016)
    CMOs Hiring Constraints:  Cell Therapy Manufacturing Expecting Future Challenges
    Figure 2. (Source: 13th Annual Report and Survey of Biopharmaceutical Manufacturing, April 2016)
    CMOs Hiring Constraints:  Cell Therapy Manufacturing Expecting Future Challenges
    Figure 3. (Source: 13th Annual Report and Survey of Biopharmaceutical Manufacturing, April 2016)
    Related CONTENT
    • Reshaping the Pharmaceutical Supply Chain
    • Spark Therapeutics Appoints CTO
    • Manufacturing Equipment Trends
    • Catalent Acquires Delphi Genetics
    • Aevitas Therapeutics Appoints President and CEO
    Eric S. Langer, BioPlan Associates03.07.17
    Hiring has become increasingly challenging as new technologies and integration of better bioprocess put greater demands on staff training and hiring. Biomanufacturing improvements demand different skill sets as well as understanding how novel technologies at R&D scale may not be feasible at commercial scale. One such area is in cell therapy manufacturing, where current bioprocessing strategies are going to be bottlenecked by the lack of trained staff.

    Other areas, such as continuous processing devices, expanding automation, multi-column, computer-controlled downstream purification, and implementing flexible bioprocessing facilities will be throttled by the inability to hire and train operators to run these new processes. Staff training to ensure productivity will lag and be outstripped by the lack of available expertise. Some of the first to be hit by hiring constraints will be the contract manufacturing organizations (CMOs) where multiple products and campaigns are run, and new technologies are often first introduced. 

    As the demand for innovation in biomanufacturing continues, the investment considerations must also be made for ensuring staff expertise and training. According to BioPlan Associates’, “13th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production,”1 of the 222 qualified industry executives, we found that about 1 in 4 bioprocessing professionals see what is coming down the pike, and recognize the need to address their training and hiring to avoid capacity constraints (see Figure 1). 

    Industry segments likely to be hit hardest
    One of the bioprocessing segments likely to be hit the hardest is in cell therapy. This innovative field is emerging as one of the most important trends (see Figure 2). In 2016, the segment was noted as the fourth most important biomanufacturing trend area. This is significant, considering the small size of these industry sectors. Further, very few mainstream biopharmaceutical professionals have had any actual involvement with these products, so it is not unexpected that this was the first year that cell therapy made the list.

    Better manufacturing technologies needed
    A number of innovative cellular and gene therapies are in development, and R&D and investments in these fields are rapidly growing. Although approvals and markets remain very small, by the standards of the mainstream (bio)pharmaceutical industry, this is likely to change as the first clinical trials are successfully concluded. And although today, the vast majority of cell and gene therapies in development are targeted to orphan, often super-orphan, indications, this is going to change as well. 

    Many developers today are academic spin-off research facilities, and some are primarily interested in showing proof-of-principle. Thus, there is a lack of needed expertise in development of manufacturing platforms appropriate for broad, large-market cell therapies. Manufacturing technologies currently used for most cell and gene therapies are often open (vs. closed, aseptic) systems, e.g., manual pipetting with cell cultured in flasks, roller bottles, etc., rather than modern bioreactors. Cell isolation, manipulation and culture remains yet to be automated, and current manufacturing is labor-intensive and expensive. 

    For example, a single autologous—using patient’s own cells for return to that patient—unit often requires weeks of work by multiple staff in a dedicated cleanroom.  This is among the reasons that make cell and gene therapies very expensive. Compared to current therapeutics, many or most cell and gene therapies will be curative with a single dose or single manufactured unit. This need for only a single one-time dose combined with unprecedented high costs for manufacturing, could lead insurers to avoid reimbursing for these therapies for which COGs of a single unit alone are roughly comparable with those for a commercial-scale bioreactor run producing many thousands of doses.

    There is also a general lack of industry knowledge about how companies will actually commercially manufacture cell therapy products in development. Further, making these cost-effective will be critical for both patients and payers. With current total cell/gene therapy production around 10,000 patient units/year, orders of magnitude growth in manufacturing capacity will be needed, first for later-stage trials and then even more for commercial manufacturing.   

    Staffing problems ahead
    Staffing problems are likely to outstrip issues like facility or cleanroom availability. Manufacturing expertise, or lack thereof, is likely a future bottleneck for growth in cell and gene therapies. Manufacturing live cells as end products is much more complex than producing non-living proteins, antibodies, etc. Bioprocessing professionals with experience in cell and gene therapies are relatively rare today. And gene/cell therapy manufacturing-related positions need high levels of expertise, despite often being repetitive and stressful. Today, staff appear to be over-qualified and it has been reported that six months of additional training is needed, even for currently trained bioprocessing staff. Process development staff for cell and gene therapies are particularly in short supply (see Figure 3).

    In our study, we asked respondents to identify job positions at their facility they are currently having difficulty filling. Process development (PD) jobs topped the list, led by upstream PD staff (36.4%) and downstream PD staff (35.1%). Also within the top five jobs most challenging to hire for were process engineers (29.9%), downstream operations staff (22.1%) and upstream operations staff (22.1%). 

    In cell and gene therapy, this on-going hiring challenge will further confound growth of manufacturing capacity to levels needed to support even just a few non-orphan-type products. And many industry observers have described a pending capacity crunch, if and when product approvals occur. CMOs and others involved in cell and gene therapies are likely to experience increased demand, so manufacturing capacity may be at a premium in coming years, as available staff keep busy.

    We can also expect a large number of new players to enter the field in coming years, particularly if new technologies and automation provide viable options for cost-effective commercial manufacturing. Yet even here, staffing to ensure technical expertise is on-hand will be a challenge. 

    The manufacturing capacity situation with cell and gene therapies could be likened to the monoclonal antibodies industry sector in the early 1990s, when the industry faced potentially very serious capacity crunches. Even all available/idle worldwide capacity at the time was not sufficient to manufacture what would be needed to support just a few blockbuster (>$1 billion/year) products. At the time, developers and CMOs responded by constructing many ≥100,000 L manufacturing facilities anchored by multiple ≥10,000 L bioreactors. Growth in cell and gene therapies manufacturing, if supported by comparable expansion of bioprocessing infrastructure, could be even quicker than the monoclonal antibodies capacity expansion. 

    Ultimately, the industry will respond by building needed facilities, automation and capacity. However, the availability of trained staff to run these high-tech operations may be the slowest bottleneck to resolve. In particular, the many small companies dominating the cell therapy field will have few viable options for cost-effectively manufacturing their products for large, commercially viable markets. Cell and gene therapies have a very promising future, and these therapies could revolutionize many disease treatments. But a lot of work remains to prepare for this, and hiring difficulties aren’t going away. CP

    Cell & Gene Therapy Explained
    Cellular therapies involve the culture of cells, usually from humans, for therapeutic administration. Gene therapies involve the use of genetic vectors to genetically transform cells for therapeutic administration, either ex vivo gene therapy, where cells are transformed, cultured and cells administered to patients, the current predominant approach, and in vivo gene therapy, where the genetic vectors are administered directly into patients. Further, cell/gene therapies may be classed based on their source/methods of manufacturing, with autologous cell/gene therapies involving administration of the patient’s own cultured cells and allogeneic cell/gene therapies involving administration of the same cells to multiple patients, with their manufacture involving batches/lots larger than 1 patient unit.


    References
    1. 13th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, BioPlan Associates, Inc. Rockville, MD., April 2016.
    Survey Methodology: The 2016 Thirteenth Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production yields a composite view and trend analysis from over 222 responsible individuals at biopharmaceutical manufacturers and contract manufacturing organizations (CMOs) in 30 countries. The methodology also included over 150 direct suppliers of materials, services and equipment to this industry. This year’s study covers such issues as: new product needs, facility budget changes, current capacity, future capacity constraints, expansions, use of disposables, trends and budgets in disposables, trends in downstream purification, quality management and control, hiring issues, and employment. The quantitative trend analysis provides details and comparisons of production by biotherapeutic developers and CMOs. It also evaluates trends over time, and assesses differences in the world’s major markets in the U.S. and Europe.


    Eric S. Langer
    BioPlan Associates

    Eric S. Langer is president and managing partner at BioPlan Associates, Inc., a biotechnology and life sciences marketing research and publishing firm established in Rockville, MD in 1989. He is editor of numerous studies, including “Biopharmaceutical Technology in China,” “Advances in Large-scale Biopharmaceutical Manufacturing”, and many other industry reports.  elanger@bioplanassociates.com  301-921-5979.  www.bioplanassociates.com
    Related Searches
    • china
    • Aseptic
    • Biomanufacturing
    • biotechnology
    Suggested For You
    Reshaping the Pharmaceutical Supply Chain Reshaping the Pharmaceutical Supply Chain
    Spark Therapeutics Appoints CTO Spark Therapeutics Appoints CTO
    Manufacturing Equipment Trends Manufacturing Equipment Trends
    Catalent Acquires Delphi Genetics Catalent Acquires Delphi Genetics
    Aevitas Therapeutics Appoints President and CEO Aevitas Therapeutics Appoints President and CEO
    MaxiVAX, Minaris Enter Cell Therapy Mfg. Agreement MaxiVAX, Minaris Enter Cell Therapy Mfg. Agreement
    Evonik Strengthens Partnership with BioNTech on COVID-19 Vaccine Evonik Strengthens Partnership with BioNTech on COVID-19 Vaccine
    Catalent, Trizell Enter Cell Therapy Deal Catalent, Trizell Enter Cell Therapy Deal
    The Future of Vaccines and Biologics The Future of Vaccines and Biologics
    Cognate BioServices, Nucleus Biologics Form Cell & Gene Therapy Partnership Cognate BioServices, Nucleus Biologics Form Cell & Gene Therapy Partnership
    Delivering Custom Client Solutions Delivering Custom Client Solutions
    Evozyne, Takeda Ink Strategic Protein Design Agreement Evozyne, Takeda Ink Strategic Protein Design Agreement
    Lilly Completes $1B Acquisition of Prevail Lilly Completes $1B Acquisition of Prevail
    Bone Therapeutics, Rigenerand Ink Cell Therapy Deal Bone Therapeutics, Rigenerand Ink Cell Therapy Deal
    Cognate BioServices Announces Major Expansion Cognate BioServices Announces Major Expansion

    Related Columns

    • Biologics, Proteins, Vaccines
      Vaccines 2021

      Vaccines 2021

      Looking at the behavioral economics of vaccinations.
      Ben Locwin, Contributing Editor 01.27.21

    • Biologics, Proteins, Vaccines
      It Takes a Vaccine… To End The Pandemic [У нас есть хорошая вакцина]

      It Takes a Vaccine… To End The Pandemic [У нас есть хорошая вакцина]

      Race for the vaccines is heating up.
      Ben Locwin, Contributing Editor 09.09.20

    • Biologics, Proteins, Vaccines
      Outsourcing in China: How far can it go?

      Outsourcing in China: How far can it go?

      China’s biopharmaceutical services market is on pace to top $1 billion by 2021
      Vicky Qing Xia, BioPlan Associates 07.15.19


    • Biologics, Proteins, Vaccines | Drug Development
      The Future Is… Therapeutic

      The Future Is… Therapeutic

      As cell and gene therapies rise, so too does outsourcing
      Ben Locwin 06.13.19

    • Biologics, Proteins, Vaccines
      Innovate UK Grant Supports Viral Vector Manufacturing

      Innovate UK Grant Supports Viral Vector Manufacturing

      Cobra Biologics talks about its recently awarded $3.4 million capital infrastructure investment
      Betsy Louda, Associate Editor 04.10.18

    • Biologics, Proteins, Vaccines | Injectables
      A World of Innovation

      A World of Innovation

      The importance of innovation in the injectable business and the hurdles a CDMO faces
      Claudia Roth, Vetter Pharma-Fertigung GmbH & Co. KG 11.07.17


    • Biologics, Proteins, Vaccines
      India is an Emerging Hub  For Low-cost Vaccines

      India is an Emerging Hub For Low-cost Vaccines

      Improvising basic vaccines to enhance stability, efficacy and compliance
      S. Harachand, Contributing Editor 11.07.17

    • Biologics, Proteins, Vaccines
      Flu Season is Upon Us

      Flu Season is Upon Us

      My chance and capricious Monday afternoon run-in with antiscience nonsense
      Ben Locwin, Contributing Editor 11.07.17

    • Biologics, Proteins, Vaccines
      Trends in New Technologies & Budgets

      Trends in New Technologies & Budgets

      Budget increases in biopharmaceutical industry indicate future growth
      Eric S. Langer, BioPlan Associates 06.06.17


    • Biologics, Proteins, Vaccines

      Biomanufacturing Trends and Outlook 2017: Where Is It All Going?

      A look at the technological advances permeating (bio)pharma manufacturing
      Ben Locwin, Contributing Editor 04.20.17

    • Biologics, Proteins, Vaccines

      Year-End Trends in Biopharma Contract Manufacturing

      Budgets are flattening, but some CMOs are well positioned for growth
      Eric S. Langer, BioPlan Associates 11.09.16

    • Biologics, Proteins, Vaccines

      Economics of In-House Buffer Preparation

      Evaluating the cost effectiveness of keeping basic ops in-house
      Eric S. Langer, BioPlan Associates 09.08.16


    • Biologics, Proteins, Vaccines | cGMP Manufacture | GMPs/GCPs | Preclinical Outsourcing | Process Development | Risk Management

      Getting to Yes

      The critical attributes CMOs need to demonstrate to win business
      Eric S. Langer, BioPlan Associates 07.14.15

    • Biologics, Proteins, Vaccines | Biosimilars | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Inspections | Logistics | Lyophilization | Methods Development | Process Development | QA/QC | Serialization | Supply Chain | Validation

      CMOs Facing Significant Capacity Constraints

      Downstream purification creating chronic problems
      Eric S. Langer, BioPlan Associates 06.02.15

    • Biologics, Proteins, Vaccines | Biosimilars | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Lyophilization | Process Development

      7 Top Trends in Biomanufacturing Outsourcing

      Keep your eye on these trends in 2015.
      Eric S. Langer and Jean-Claude Lupis, BioPlan Associates 01.29.15

    Trending
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • AbbVie Opts To Acquire Mitokinin
    • Bormioli Opens New Glass Research Center
    • WuXi AppTec Completes OXGENE Acquisition
    • Arcline Investment Acquires ChargePoint Technology
    Breaking News
    • Fusion Pharmaceuticals Acquires IPN-1087
    • Strata Oncology Unveils Strata PATH Trial
    • Alimentiv Acquires McDougall Scientific
    • Q BioMed Inks Strontium89 Supply Pact
    • PCI Pharma Services Appoints SVP, CFO
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Low Levels of Vitamin D and Calcium Linked to COVID-19 Severity
    Probiotic Evidenced to Assist Digestive Recovery from a Complex Surgery
    AHPA Submits Comments to FDA on Proposed Traceability Rule
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    AOC Announces EMEA Price Increase
    Mule-Hide Products Co. Introduces Seal-Fast Liqui-Flash
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    NAMSA Acquires American Preclinical Services
    Quidel's QuickVue At-Home COVID-19 Test Earns EUA
    Memic Receives FDA Marketing Authorization for Hominis
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Fusion Pharmaceuticals Acquires IPN-1087
    Strata Oncology Unveils Strata PATH Trial
    Alimentiv Acquires McDougall Scientific
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    IT Cosmetics Supports Women’s Confidence
    Inter Parfums Reports a Strong Fourth Quarter
    Universal Engraving Announces New President
    Happi

    Latest Breaking News From Happi

    Croda International Acquires Alban Muller
    Givaudan Active Beauty Launches Omegablue
    Sozio Acquires Scentessence
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Abbott Label installs Domino K600i dual bar digital UV inkjet printer
    Crossmark turns to Eagle Systems for cold foil
    Maxcess launches Tidland PressureMax Airshaft Pressure Monitoring System
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Domtar Completes Sale of Personal Care Business
    Mitsui to Sell Chinese Nonwovens Business
    Dr. J's Disinfectant Wipes Approved for Distribution in CA
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    FDA Approves Accufix Surgical's Accu-Joint Hemi Implant
    FDA OKs Q-Collar Device to Protect Athletes’ Brains During Head Impacts
    SeaSpine Releases Reef TO (TLIF Oblique) Interbody System
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login